Background and objective Most of the carcinogenic effects of polycyclic aromatic hydrocarbons present in tobacco smoke are mediated by the aryl hydrocarbon receptor (AHR), a ligand-dependent transcription factor that regulates tobacco-induced expression of carcinogen metabolic enzymes. We hypothesized that genetic variations in AHR might confer individual susceptibility to lung cancer.
Background and objective Most of the carcinogenic effects of polycyclic aromatic hydrocarbons present in tobacco smoke are mediated by the aryl hydrocarbon receptor (AHR), a ligand-dependent transcription factor that regulates tobacco-induced expression of carcinogen metabolic enzymes. We hypothesized that genetic variations in AHR might confer individual susceptibility to lung cancer.
Methods Eight selected single-nucleotide polymorphisms in AHR were genotyped using the Illumina SNP genotyping BeadLab platform in a case-control study of 500 lung cancer patients and 517 cancer-free controls in a Chinese population.
Results We found that significantly increased lung cancer risk was associated with heterozygous genotypes of rs2158041 (adjusted odds ratio = 1.53 and 95% confidence interval = 1.17-1.99 for GA, compared with the GG genotype) and rs7811989 (adjusted odds ratio = 1.48 and 95% confidence interval = 1.13-1.93 for GA, compared with the GG genotype), although these two single-nucleotide polymorphisms were in linkage disequilibrium. Furthermore, haplotype analysis revealed significant differences in haplotype distributions of AHR between cases and controls (Global P = 1.38e-5). We also observed statistically significant interaction between the polymorphism rs2066853 (p.Arg554Lys) and cumulative cigarette smoking as a discrete or continuous variable (P = 0.033 and 0.019, respectively), and the Lys/Lys genotype conferred an increased risk of lung cancer in the heavy smokers (adjusted odds ratio = 3.36 and 95% confidence interval = 1.07-10.55). 
Conclusion

Introduction
Tobacco smoking is a primary etiologic factor for lung cancer, and about 10-20% of long-term smokers develop lung cancer in their lifetime [1, 2] . It is well established that susceptibility to lung cancer may in part be attributable to interindividual variation in metabolic activation or detoxification of tobacco carcinogens [3] [4] [5] , suggesting the importance of genetic determinants in lung cancer etiology, including the gene-environment interaction between genetic polymorphisms and environmental factors, such as smoking.
Exposure to polycyclic aromatic hydrocarbons (PAHs), a major class of potent tobacco procarcinogens, results in a wide range of toxic and carcinogenic responses in humans [6] . Most of the biological effects of PAHs are mediated by the aryl hydrocarbon receptor (AHR), a ubiquitously expressed ligand-activated transcriptional factor, which upon ligand binding activates the transcription of genes coding multiple phase I and phase II enzymes [7] . Phase I enzymes, such as CYP1A1 and CYP1B1, and phase II enzymes, such as glutathione S-transferases, in turn, participate in the metabolism of PAHs [8] [9] [10] . Each of these enzymes is expressed in human lung and is inducible through the activation of the AHR [11] . Therefore, AHR plays a critical role in the regulation of carcinogen metabolism in the lung. Benzo[a] pyrene (BaP), one of the most important members of PAHs in cigarette smoke, is a major potent carcinogen implicated in the etiology of lung cancer through the induction of BaP diol epoxidation-DNA adducts through the AHR pathway [12, 13] . There is direct evidence that BaP carcinogenicity is lost in the AHR-null mice [14] ; besides, resveratrol, a natural competitive inhibitor of the AHR, could protect the lung from DNA damage and apoptosis caused by BaP, suggesting that the AHR is involved in the carcinogenesis initiated by BaP, especially in the lung [15] . In laboratory animals, genetic variations in AHR can dramatically alter its affinity for ligands or transcriptional regulation, leading to substantial differences in sensitivity to biochemical and toxic effects of PAHs and structurally related halogenated aromatic hydrocarbons, such as 2,3,7,8-tetrachlorodibenzo-p-dioxin [16] [17] [18] .
Human lung cancer is a well-known example of environmentally induced carcinogenesis, which occurs through a complex multistage process as a result of the combination of carcinogen exposure and genetic susceptibility [19] . Human beings vary widely in their sensitivity to toxic effects of xenobiotic chemicals, and tobaccoinduced expression of carcinogen metabolic enzymes in the lung also has a wide interindividual variation [20, 21] . It has been known for several decades that phenotypic diversity exists among humans in the responses mediated by the AHR [22] [23] [24] . As the AHR is a central factor that regulates enzyme induction in response to tobacco carcinogens, we hypothesized that genetic variations in AHR may confer individual susceptibility to lung cancer.
To test this hypothesis, we genotyped for eight AHR common single-nucleotide polymorphisms (SNPs) including one nonsynonymous SNP (p.Arg554Lys) in exon 10 and evaluated potential gene-smoking interaction in lung cancer risk in a case-control study of 500 incident lung cancer cases and 517 age and sex frequency matched cancer-free controls in a Chinese population.
Materials and methods
Study population
The study population and patients' characteristics have been described elsewhere [25] . In brief, this study was composed of 500 lung cancer patients and 517 cancerfree controls. All the participants were genetically unrelated ethnic Han Chinese and were from Nanjing City and surrounding regions in southeastern China.
Patients newly diagnosed with histopathologically confirmed lung cancer were consecutively recruited between July 2002 and December 2004 at the Cancer Hospital of Jiangsu province (Nanjing) and the First Affiliated Hospital of Nanjing Medical University, Nanjing, China with a response rate of 90.5% without the restrictions of age, sex, and histology. The exclusion criteria included self-reported cancer history and previous radiotherapy and chemotherapy for unknown disease conditions. Cancer-free controls were randomly selected from 10 500 individuals who participated in a communitybased screening program for noninfectious diseases conducted in Jiangsu province during the same period when the patients were recruited, with a response rate of 83.8%. The exclusion criteria for the control participants were the same as those for the case patients. All the control participants were frequency matched to the patients by age (± 5 years), sex, and residential area (urban or rural areas). Each participant was scheduled for an interview after a written informed consent was obtained, and a structured questionnaire was administered by interviewers to collect information on demographic data and environmental exposure history including tobacco smoking. Smoking status and cumulative smoking dose were used to evaluate the smoking exposure. For the smoking status, those who had smoked less than one cigarette per day in less than 1 year in their lifetime were defined as nonsmokers; those smokers who had quit for longer than 1 year were considered as former smokers; otherwise they were considered as current smokers. In addition, pack-years smoked [(cigarettes per day/20) Â years smoked] were calculated to indicate the cumulative smoking dose, which took one's total consumption of cigarette smoking into account. Family history of cancer was defined as any self-reported cancer in firstdegree relatives (parents, siblings, or children). After the interview, an approximately 5-ml venous blood sample was collected from each participant. The study was approved by the institutional review boards of Fudan University.
Selection of single-nucleotide polymorphisms of aryl hydrocarbon receptor
The human AHR gene encompasses 47.146 kb and is located on chromosome 7p15. As this study was initiated in January 2005 when the SNP density of phase I HapMap SNP database was not adequate (14 SNPs were included, eight of which had a minor allele frequency Z 5%), we chose SNPs from both the HapMap and dbSNP databases. In the genetic model of AHR (contig accession NT_007819.16), it had 12 exons and 11 introns with 65 SNPs listed in the dbSNP Build 121. To capture the majority of common variants across this gene, an algorithm to score the SNPs was developed and a set of SNPs were selected based on their final scores. The detailed procedure has been described elsewhere [26] . In brief, for a SNP, the following criteria were considered: (i) interdistance between two adjacent SNPs; (ii) heterozygosity; (iii) functional relevance; (iv) compatibility with the genotyping platform. As a result, eight SNPs (rs713150, rs6951212, rs3802083, rs1476080, rs2158041, rs7811989, rs2074113, and rs2066853) were chosen for genotyping in this study, of which one was a nonsynonymous variant rs2066853 (p.Arg554Lys) in exon 10 and seven were intronic variants.
Genotyping assays
We genotyped the SNPs of rs713150, rs6951212, rs3802083, rs1476080, rs2158041, rs7811989, and rs2074113 by using the Illumina SNP genotyping BeadLab platform (Illumina Corp, Foster City, California, USA) at the Chinese National Human Genome Centre and one additional SNP rs2066853 (p.Arg554Lys) located in exon 10 by using the fluorogenic 5 0 nuclease Taqman assay (Applied Biosystems, Foster City, California, USA) at Fudan University. The information on assay conditions and the primers and probes is available upon request. For the Illumina high-throughput genotyping platform, more detailed description of quality control method and each of the steps are available in our previously published paper [25] and the HapMap website (http:// www.hapmap.org/downloads/protocols_overiview.html). As 37 genomic DNA samples of case patients and 18 of control participants have run out in the former genotyping assay, there were 463 samples of patients and 499 samples of controls left for the Taqman assay of rs2066853. Two no-template controls and two duplicated samples in each 384-well format were used for quality control procedure. Four hundred and fifty (97.2%) of 463 patients and 489 (98.0%) of 499 controls were successfully genotyped in this locus. The consistency rate observed in these duplicated samples was 100%.
Statistical analyses
For each polymorphism, deviation of the genotype frequencies from those expected under Hardy-Weinberg equilibrium was assessed in the controls by a w 2 test. Genotype frequencies in patients and controls were compared using a w 2 test. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated by unconditional logistic regression analysis with adjustment for age, sex, pack-years of smoking, and family history of cancer. Stratification analyses were also performed by variables of interest, such as age, sex, smoking status (nonsmokers, former smokers, and current smokers), trichotomized pack-years of smoking [nonsmokers (0 pack-years), light smokers (r 30 pack-years), and heavy smokers (> 30 pack-years)], family history of cancer, and histological types.
The pairwise linkage disequilibrium (LD) among the SNPs was examined using Lewontin's standardized coefficient D 0 and LD coefficient r 2 [27] , and haplotype blocks were defined by the method of Gabriel et al. [28] in the publicly available Haploview software (http:// www.broad.mit.edu/personal/jcbarret/haplo/) [29] with default settings [the CI for a strong LD was minimal for (upper 0.98 and low 0.7) and maximal for a strong recombination of 0.9, and a fraction of strong LD in informative comparisons was at least 0.95]. The haplotypes were inferred from all genotype data, and haplotype (with a frequency of higher than 0.01) analyses were conducted by using Haplo.stats (http://www.mayo.edu/stagen), which is a score test based on the generalized linear model framework [30] . This program allows adjustment for possible confounding variables and provides both global and haplotype-specific tests for associations. To reduce the potential of spurious findings due to multiple testing, we conducted permutation testing to guide interpretation of nominally statistically significant associations in the single-locus, haplotype and stratification analyses. Case-control status was randomly permuted 100 000 times.
The potential gene-environment interaction between the SNPs and cigarette smoking was evaluated with the genotype-smoking joint effect and interaction models that considered cumulative smoking dose as both discrete [nonsmokers, light smokers (r 30 pack-years), and heavy smokers (> 30 pack-years)] and continuous (square root of pack-years) variables. The genotype-smoking interaction model included the following covariates: interaction term between genotypes and cumulative smoking dose (a discrete or continuous variable), genotypes, cumulative smoking dose (a discrete or continuous variable), age, sex, and family history. All the statistical analyses were performed with the SPSS15.0 software, with two-sided tests and a significant level of 0.05, unless indicated otherwise.
Results
Characteristics of the study population
The distributions of selected characteristics between lung cancer patients and controls have also been described elsewhere [25] . In brief, our frequency matching on age and sex was adequate (P = 0.661 for age and P = 1.000 for sex). The patients were, however, more likely to be smokers than the controls (77.0 vs. 51.8%), and more patients (35.4%) smoked more than 30 pack-years than did the controls (18.8%), and this difference was statistically significant (P < 0.0001). Furthermore, 24.4% of the lung cancer patients reported a family history of cancer in their first-degree relatives, which was significantly higher than that of the controls (16.8%), and this difference accounted for a significantly 60% increased lung cancer risk (OR = 1.60 and 95% CI = 1.17-2.17). Of the 500 lung cancer patients, 229 (45.8%) were adenocarcinoma, 141 (28.2%) squamous cell carcinoma, 34 (6.8%) small cell lung cancer, and 96 (19.2%) large cell, mixed cell carcinomas or undifferentiated carcinoma.
Individual single-nucleotide polymorphism association analysis
The SNP IDs, locations, and frequencies are given in Table 1 (information was updated according to the present dbSNP Build 129). All AHR genotype distributions in the controls were consistent with those expected from the Hardy-Weinberg equilibrium.
In the single-locus analyses, no significant differences in SNP allele distributions were found between patients and controls (Table 1) . We, however, observed statistically significant differences between case patients and control participants in genotype distributions for two SNPs (P = 0.0038 for rs2158041 and P = 0.008 for rs7811989) and the significance remained after applying 100 000-time permutation tests (P = 0.0193 for rs2158041 and P = 0.0407 for rs7811989).
Further logistic regression analyses revealed that in the genotypic effect model with 2 d.f., significant risks were associated with the variant genotypes of rs2158041 G/A (adjusted OR = 1.53 and 95% CI = 1.17-1.99 for GA, P = 0.002, compared with the GG genotype) and rs7811989 G/A (adjusted OR = 1.48 and 95% CI = 1.13-1.93, P = 0.004 for GA, compared with the GG genotype) ( Table 2) .
Furthermore, we performed stratified analyses by selected variables and histological types on the SNPs of rs2158041G/A, rs7811989G/A, and rs2066853G/A. As shown in Table 3 , compared with the wild-type genotype, the risk effects were almost similar in magnitude and direction to the point estimates obtained from fitted ORs of rs2158041 GA genotype among the subgroups stratified by age, sex, smoking status, pack-years of smoking, family history of cancer, and histological types, although the significance was mostly diminished in some subgroups because of reduced sample sizes. The risk effects of the rs7811989 GA genotype had the same trend as that of the rs2158041 GA genotype among all subgroups (data not shown). As for rs2066853, adjusted ORs of the AA genotype versus the GG genotype increased significantly as the number of pack-years increased, and the elevated risk was statistically significant among the heavy smokers (adjusted OR = 3.36 and 95% CI = 1.07-10.55, P = 0.038). This was, however, no longer significant after the multipletesting correction (P > 0.05).
Haplotype block structure and haplotype analysis Table 1 ). Table 4 summarizes the associations between frequencies of the haplotypes and risk of lung cancer. Global score test showed statistically significant differences in the AHR haplotype distributions between case patients and control participants (Global P = 1.38e-5). After adjusting for confounding factors, the risk of lung cancer was significantly increased among individuals carrying the haplotype 'TAAGGAG' (adjusted OR = 12.85 and 95% CI = 2.98-55.53, P = 0.0007), compared with those carrying the most common haplotype 'CGCGGCG'. These results remained significant after the correction of 100 000-time permutation tests for multiple testing. Furthermore, one highly protective haplotype 'TAAGGCG' with a 60% reduction in risk of developing lung cancer was identified among the heavy smokers (adjusted OR = 0.40 and 95% CI = 0.18-0.89, P = 0.025). 
Gene-smoking interaction analysis
As shown in Table 5 , the genotype-smoking joint effect analyses revealed that the adjusted ORs of the 'GA' versus 'GG' and 'AA' versus 'GG' genotypes increased significantly as the number of pack-years increased, suggesting that the effect of the rs2066853 appeared to be strongly modified by cumulative cigarette smoking. Notably, the magnitude and statistical significance for the 'AA' versus 'GG' genotype were larger and stronger, respectively, than that for the 'GA' versus 'GG 'comparison, suggesting a gene-dose relationship for the number of the variant A allele. A statistically significant multiplicative interaction between rs2066853 genotypes and cumulative smoking dose was observed when the genotype-smoking interaction model considered cumulative smoking dose as both discrete [nonsmokers, light smokers (r 30 pack-years), and heavy smokers (> 30 pack-years)] and continuous variables (square root of packyears) with P = 0.033 and 0.019, respectively. However, no interaction between the genotypes and cigarette exposure was found for other polymorphisms. Table 1 . One haplotype block (colored) was defined by the Haploview program using the approach given in Gabriel et al. 
Discussion
In this lung cancer case-control study in a Chinese population, we found, for the first time, that the variant genotypes of two (rs2158041 and rs7811989) of eight selected SNPs in AHR were significantly associated with lung cancer risk, although these two SNPs were in strong LD. Furthermore, there was significant difference in the haplotype distributions of AHR between case patients and control participants. All the above positive associations derived from single-locus and haplotype analyses remained significant after correction by permutation tests. However, considering the ambiguity in haplotype inference and the missing data (especially rs2066853), the validity of information derived from the rare haplotypes warrants further studies. We also, for the first time, presented statistical evidence of significant interaction between the rs2066853 SNP and cumulative cigarette smoking in the risk of lung cancer. These findings support our hypothesis that AHR polymorphisms and the potential gene-smoking interaction may contribute to susceptibility to lung cancer. Larger studies with ethnically diverse populations are warranted to confirm our findings.
AHR is ubiquitously distributed in cells and tissues of humans and has a long evolutionary history [31, 32] . The high degree of conservation in the primary structure of the human AHR implies that this protein has important biological functions [33] . In addition to regulating responses to environmental contaminants, a recent study provided further evidence that the AHR pathway may also play an important role in cigarette smoke-mediated cyclooxygenase-2 and prostaglandin production in human lung fibroblasts and thus may contribute to tobacco-associated inflammation and lung diseases, including lung cancer [34] . Moreover, AHR modulates cellular signaling pathways critical to cell-cycle regulation, differentiation, mitogen-activated protein kinase cascades, immediate-early gene induction, and functions of the RB protein [35] . It is important to note that AHR is associated with increased oxidative stress and tumor promotion independent of the CYP1 activity [36, 37] . In the absence of exogenous AHR ligands (such as tobacco smoke components), AHR overexpression upregulated the expression of CYP1B1 in the early stage of lung adenocarcinoma, and elevated AHR expression in lung adenocarcinoma cells could enhance intracellular oxidative stress and promote cell growth [38] . Taken together, AHR is one of the strongest candidate genes for susceptibility to lung cancer.
The role of polymorphisms in the AHR gene in lung cancer risk has been examined in epidemiological studies in Japanese, French and Korean populations, in which three common SNPs (rs7796976 G/A in 5 0 -UTR, rs2074113 G/T in intron 7 and rs2066853 G/A in exon 10) were investigated but none of the genotypes was found to be associated with lung cancer risk [39] [40] [41] . In our study, we used a polymorphism selection strategy combing both hypotheses-driven (nsSNPs) and hypotheses-free (tagSNPs) approaches to identify the most representative SNPs in AHR. As, however, we chose SNPs from both the HapMap phase I and dbSNP databases, in which the specific LD among most SNPs of the AHR gene was not available at that time, we could only try to minimize the strong LD of any pair of candidate SNPs based on their intermarker distance and heterozygosity, which may be potentially redundant. In the CHB (45 Han Chinese in Bejing, northern China) genotyped data of AHR, released in phase II of the International HapMap Project (HapMap Data Rel 22/ phase II Apr 07), 17 SNPs (rs7796976 and rs2074113 not included) of AHR have a minor allele frequency Z 5%. As shown in supplementary Fig. 1, 15 of the 17 SNPs are in LD, which comprise one LD block. Five SNPs in this block, two SNPs (rs713150 and rs6951212) in preblock region, and one reported SNP rs2074113 that was not included in phase II were selected in our study. The seven SNPs (rs2074113 excluded) were able to capture 15 of these 17 informative alleles with a minimal LD variable r 2 threshold of 0.7, and 14 (93%) of captured alleles have pairwise LD with r 2 > 0.8. Therefore, the genetic variants investigated in our study captured most of common variants in the gene in the Chinese population. However, one reported SNP rs7796976 was not included in this study. As there is no information regarding allele frequencies of this SNP in Chinese population up to now, we do not know whether or not it is in LD with any of our investigated SNPs. To the best of our knowledge, except for SNPs rs2074113 and rs2066853, none of the other selected SNPs in our study has been previously investigated in cancer susceptibility.
Consistent with the earlier studies, no overall effects for rs2074113 and rs2066853 on lung cancer risk were observed in this study. However, two other SNPs (rs2158041 and rs7811989 in nearly complete LD), both residing in the intronic regions, were found to be significantly associated with increased risk of lung cancer. Accumulating evidence has indicated the importance of intronic polymorphisms as markers for cancer susceptibility. For example, intronic SNPs in p53 [42] and ataxia telangiectasia mutated [43] were associated with increased risk of lung cancer and breast cancer, respectively. These intronic SNPs could potentially produce alternative splicing of their gene products or they are in tight linkage with other causal loci or genes. However, the exact location and biological functions of the real causal SNPs in AHR is of great interest and warrant further investigation.
Interestingly, for some SNPs, we found that the risk effect seemed to be significant in the heterozygotes but not in the homozygotes. It is not uncommon that heterozygous genotypes seem to confer the greatest risk as reported in molecular epidemiological association studies with genotyping data in the literature. Although current knowledge has not provided a convincing explanation for such a finding, there are several possibilities that may explain these seemingly peculiar observations. Technically, such a bias toward the heterozygotes could result from a systematic genotyping error, but this is unlikely to occur in the Illumina assay that has a stringent quality control. It has been postulated that the heterozygous genotype may be in LD with other susceptibility loci, or some of homozygotes in combination with other adverse genotypes may have been embryogenically lethal or heterozygotes may have impaired functions because of the potential imbalance of the resultant protein structure [44] . These hypotheses, however, need to be further tested in in-depth molecular mechanistic studies in the future. Alternatively, because of the relatively small numbers of the variant homozygotes observed in both patients and controls, the effect of the variant homozygotes might more likely be affected by any selection bias inherent in such hospital-based retrospective study than the heterozygotes which are often present in a much larger number of observations, or simply there is not enough statistical power to detect any real effect among the variant homozygotes [45] . These can only be overcome by performing additional mechanistic studies and much larger association studies in the future.
The interplay between SNPs of the AHR gene and cigarette smoking with respect to lung cancer risk has not been investigated in the earlier studies. With the advantage of detailed measures of cigarette smoking, our results indicated that the effect of the p.Arg554Lys (rs2066853) seemed to be strongly modified by cigarette smoking and that the Lys/Lys genotype conferred a statistically significantly high risk of lung cancer in the heavy smokers who smoked more than 30 pack-years. As the potential interaction between rs2066853 and smoking was, however, gradually developed by a list of testing procedures, future replication studies in other ethnic populations should be performed to substantiate this observation. As indicated in the literature [46] , a possible definition of gene-environment interaction is that it occurs when a genetic and environmental exposure collectively cause a disease outcome in some or all patients. As this association was restricted to the heavy smokers, a role for the p.Arg554Lys in such a subgroup inferred a causal association between PAHs and lung cancer. Several lines of evidence may support this finding. The arginine to lysine substitution at codon 554 exists in D/E-rich transactivation domain of AHR, which may permit finely tuned modulation in downstream gene expression including the CYP1A1 induction triggered by smoking [33] . CYP1A1 and its correlated catalytic activities are enhanced in the lungs of most cigarette smokers, presumably resulting from concentrated exposure of the lung to PAHs and other AHR ligands in smoke [33] . Furthermore, more than a dozen laboratories independently found correlations between the high CYP1A1 inducibility phenotype and lung cancer in cigarette smokers [8] . Therefore, the variant of rs2066853 SNP may be heavily dependant on the cumulative dose of the cigarette smoking for its carcinogenic potential, that is, there is no increased risk for the variant genotype in the absence of high dose of cigarette smoking. Smart and Daly [47] reported that cultured lymphocytes from individuals carrying at least one Lys allele had significantly elevated CYP1A1 activity and expression in a Caucasian population. Contrary to the observation of Smart and Daly, several studies, however, did not find any evidence for altered CYP1A1 inducibility associated with p.Arg554Lys [39, 40, 48, 49] . This discrepancy may be due to inclusion of different ethnic groups and the limitation of the methods for assessing the effect of the AHR genotype on the induction phenotype in humans. Therefore, the extent of influence of p.Arg554Lys on the gene functions remains to be elucidated in further studies.
stringent threshold of genome-wide significance, to some extent, some loci may be missed because the causal variants have smaller overall effects or they are in low LD with SNPs on the genotyping arrays [53] . Further genome-wide scans in populations with detailed data on smoking exposure and intensity of smoking with diverse ethnic groups [54] are needed to unravel possible association between the AHR locus and lung cancer risk or related gene-environment interaction.
Several limitations are inherent in this type of casecontrol study and must be noted. First of all, this study was a hospital-based case-control study with patients recruited from hospitals and controls selected from the community, and thus selection bias may lead to spurious findings. Potential confounding bias was, however, minimized by frequency-matching of the controls to the patients by age, sex, and area and further adjustment for potential confounding factors in the analyses. To reduce potential spurious findings because of multiple testing, we conducted permutation testing to guide interpretation of nominally statistically significant associations. Second, the sample size of this study was relatively small, which may produce false-positive or false-negative results, whereas the genotype frequency was low or stratified analyses were performed. Therefore, further prospective studies will be needed in a larger and ethnically diverse population to validate the findings. Finally, our study lacked information on other exposures such as dietary consumption, occupational and environmental exposure, which might act as potential confounding factors. Further studies are needed to address whether these factors also modify genetic susceptibility to lung cancer.
In conclusion, in this case-control study in a Chinese population, we provided evidence that some common genetic variants of AHR may modulate risk of lung cancer. In particular, our results support the notion that some genetic effect that may not be detectable in a single-locus analysis can be unraveled when geneenvironment interaction is considered. However, large prospective studies with ethnically diverse populations and functional evaluation are warranted to further elucidate the impact of genetic variation in AHR on lung cancer susceptibility.
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